Sunshine Little, MD
Family Medicine · Carencro, LANPI 1881803138
Payments from drug & device makers
Across 166 payments — averaging $16.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$431
- Novo Nordisk$359
- Lilly USA, LLC$274
- AstraZeneca$263
- Takeda Pharmaceuticals U.S.A., Inc.$188
- Sumitomo Pharma America, Inc.$135
- plus $1K from 24 others
What the payments were for
- Food & beverage$2,671100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 24 | $431 |
| Novo Nordisk | 27 | $359 |
| Lilly USA, LLC | 18 | $274 |
| AstraZeneca | 17 | $263 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $188 |
| Sumitomo Pharma America, Inc. | 6 | $135 |
| Boehringer Ingelheim | 9 | $129 |
| GSK | 7 | $112 |
| Exact Sciences | 7 | $111 |
| Amgen | 5 | $72 |
| Sanofi-aventis U.S. LLC | 3 | $65 |
| Phathom Pharmaceuticals, Inc. | 4 | $56 |
| Astellas Pharma US Inc | 3 | $53 |
| Kowa Pharmaceuticals America, Inc. | 3 | $52 |
| Axsome Therapeutics, Inc. | 2 | $51 |
| Pfizer | 3 | $44 |
| Shire North American Group Inc | 3 | $39 |
| Ardelyx, Inc. | 2 | $38 |
| Corcept Therapeutics | 1 | $28 |
| Currax Pharmaceuticals LLC | 2 | $25 |
| Abbott | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| Merck | 1 | $16 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $12 |
| Circassia Inc. | 1 | $12 |
| Novartis | 1 | $11 |
How this compares
$2,671 in reported general payments places this provider in the 70th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 142 | $174,892 |
| JardianceEmpagliflozin | 100 | $106,215 |
| MounjaroTirzepatide | 85 | $101,743 |
| TrulicityDulaglutide | 73 | $92,921 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 71 | $63,742 |
| LinzessLinaclotide | 63 | $48,526 |
| VascepaIcosapent Ethyl | 56 | $29,632 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $26,211 |
| JanuviaSitagliptin Phosphate | 34 | $25,210 |
| RybelsusSemaglutide | 15 | $22,994 |
| TradjentaLinagliptin | 18 | $22,162 |
| MyrbetriqMirabegron | 29 | $19,950 |
| Spiriva RespimatTiotropium Bromide | 13 | $18,735 |
| Xigduo XrDapaglifloz Propaned/Metformin | 18 | $18,604 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 11 | $14,846 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Spiriva Respimat | $129 | $210,854202 claims |
| Novo NordiskOzempic, Rybelsus | $359 | $197,885157 claims |
| Lilly USA, LLCMounjaro, Trulicity | $274 | $194,664158 claims |
| AbbVieLinzess, Synthroid | $431 | $53,087135 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $112 | $46,86865 claims |
| MerckJanuvia, Janumet Xr | $16 | $40,05645 claims |
| Astellas Pharma US IncMyrbetriq | $53 | $19,95029 claims |
| PfizerEliquis | $44 | $14,53115 claims |
| Johnson & JohnsonInvokana | $16 | $12,87421 claims |
| AstraZenecaSymbicort | $263 | $9,35417 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $188 | $5,69113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Carencro
- Clinton GuilloryMonroe$18.5M
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
- William NaboursLake Charles$3M
- Ramon VargasKenner$2.1M
- Stephen JonesNew Orleans$513K
- Joshua WhatleyLake Charles$366K
- Richard JeansonneMandeville$362K
- Kristen ThomasNew Orleans$361K
- Clint WilsonBossier City$208K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.